QUALIGEN THER.NEW DL-001
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other sol… Read more
QUALIGEN THER.NEW DL-001 (7R9) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, QUALIGEN THER.NEW DL-001 (7R9) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
QUALIGEN THER.NEW DL-001 - Net Assets Trend (None–None)
This chart illustrates how QUALIGEN THER.NEW DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for QUALIGEN THER.NEW DL-001 (None–None)
The table below shows the annual net assets of QUALIGEN THER.NEW DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to QUALIGEN THER.NEW DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
QUALIGEN THER.NEW DL-001 Competitors by Market Cap
The table below lists competitors of QUALIGEN THER.NEW DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dividend Growth Split Corp
TO:DGS
|
$52.33K |
|
AS Harju Elekter
STU:HD8
|
$52.33K |
|
Marshalls PLC
LSE:MSLH
|
$52.42K |
|
CH SHENHUA ENGY -H- (IKF.SG)
STU:IKF
|
$52.43K |
|
INTESA SANPAOLO - Dusseldorf Stock Exchang
DU:IES
|
$52.32K |
|
IP Group
LSE:IPO
|
$52.29K |
|
MINT Société anonyme
PA:ALMIN
|
$52.25K |
|
Homasote Co
PINK:HMTC
|
$52.24K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in QUALIGEN THER.NEW DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares QUALIGEN THER.NEW DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently QUALIGEN THER.NEW DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares QUALIGEN THER.NEW DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| QUALIGEN THER.NEW DL-001 (7R9) | €- | N/A | N/A | $52.33K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |